{"component": "clause", "props": {"groups": [{"size": 14, "samples": [{"hash": "hjnTMrVICDq", "uri": "/contracts/hjnTMrVICDq#commercialization-reports", "label": "Exclusive License Agreement (Icosavax, Inc.)", "score": 32.5126609802, "published": true}, {"hash": "6rXcviNTPsX", "uri": "/contracts/6rXcviNTPsX#commercialization-reports", "label": "License and Exclusive Option Agreement (Icosavax, Inc.)", "score": 32.5126609802, "published": true}, {"hash": "ff482p0msbu", "uri": "/contracts/ff482p0msbu#commercialization-reports", "label": "Exclusive License Agreement (Icosavax, Inc.)", "score": 32.364818573, "published": true}], "snippet": "Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company\u2019s and Sublicensees\u2019 efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.", "snippet_links": [{"key": "the-term-of-this-agreement", "type": "clause", "offset": [11, 37]}, {"key": "off-period", "type": "clause", "offset": [58, 68]}, {"key": "within-thirty", "type": "clause", "offset": [74, 87]}, {"key": "each-year", "type": "definition", "offset": [118, 127]}, {"key": "company-will", "type": "clause", "offset": [129, 141]}, {"key": "to-university", "type": "clause", "offset": [150, 163]}, {"key": "reports-of", "type": "clause", "offset": [172, 182]}, {"key": "to-develop", "type": "definition", "offset": [229, 239]}, {"key": "covered-by", "type": "definition", "offset": [274, 284]}, {"key": "licensed-rights", "type": "definition", "offset": [289, 304]}, {"key": "licensed-products", "type": "definition", "offset": [326, 343]}, {"key": "no-obligation-to", "type": "clause", "offset": [363, 379]}, {"key": "sales-report", "type": "clause", "offset": [474, 486]}, {"key": "performance-milestones", "type": "definition", "offset": [540, 562]}, {"key": "in-relation-to", "type": "clause", "offset": [564, 578]}, {"key": "the-performance", "type": "clause", "offset": [587, 602]}, {"key": "sufficient-information", "type": "definition", "offset": [657, 679]}, {"key": "set-out", "type": "definition", "offset": [748, 755]}, {"key": "plans-for", "type": "clause", "offset": [771, 780]}], "hash": "761ce502b4396dda749d742c51fbdaa0", "id": 1}, {"size": 11, "samples": [{"hash": "dv1QK7B0aWi", "uri": "/contracts/dv1QK7B0aWi#commercialization-reports", "label": "Collaboration and License Agreement (Facet Biotech Corp)", "score": 21.2847366333, "published": true}, {"hash": "dFAuIortDj4", "uri": "/contracts/dFAuIortDj4#commercialization-reports", "label": "Collaboration and License Agreement (Trubion Pharmaceuticals, Inc)", "score": 21.2108154297, "published": true}, {"hash": "fXtvZWd168N", "uri": "/contracts/fXtvZWd168N#commercialization-reports", "label": "Collaboration and License Agreement (Trubion Pharmaceuticals, Inc)", "score": 21.0, "published": true}], "snippet": "Each Party will keep the JCC fully informed regarding the progress and results of its Commercialization activities with respect to Collaboration Products under this Agreement.", "snippet_links": [{"key": "each-party-will", "type": "clause", "offset": [0, 15]}, {"key": "fully-informed", "type": "clause", "offset": [29, 43]}, {"key": "commercialization-activities", "type": "clause", "offset": [86, 114]}, {"key": "with-respect-to", "type": "clause", "offset": [115, 130]}, {"key": "collaboration-products", "type": "clause", "offset": [131, 153]}, {"key": "this-agreement", "type": "clause", "offset": [160, 174]}], "hash": "7d6f63c5c8db4598cf5b8e5f5d377025", "id": 2}, {"size": 10, "samples": [{"hash": "lyZ5Ace66ob", "uri": "/contracts/lyZ5Ace66ob#commercialization-reports", "label": "Exclusive Patent License Agreement (Cellectis S.A.)", "score": 31.9924716949, "published": true}, {"hash": "bzxw2zD6OFN", "uri": "/contracts/bzxw2zD6OFN#commercialization-reports", "label": "Exclusive Patent License Agreement (GT Biopharma, Inc.)", "score": 28.6084880829, "published": true}, {"hash": "kVeP0fWzxrY", "uri": "/contracts/kVeP0fWzxrY#commercialization-reports", "label": "Exclusive Patent License Agreement (Cellectis S.A.)", "score": 26.1909656525, "published": true}], "snippet": "Throughout the Term and during the Post-termination Period, and within thirty (30) days of the date specified in the schedule set forth in section 10 of the EPLA, the Licensee shall deliver to the University written reports of the Licensee\u2019s and the sublicensees\u2019 efforts and plans to commercialize the Licensed Technology and to manufacture, offer to sell, or sell Licensed Products.", "snippet_links": [{"key": "the-term", "type": "clause", "offset": [11, 19]}, {"key": "the-post", "type": "clause", "offset": [31, 39]}, {"key": "termination-period", "type": "clause", "offset": [40, 58]}, {"key": "within-thirty", "type": "clause", "offset": [64, 77]}, {"key": "the-schedule", "type": "clause", "offset": [113, 125]}, {"key": "section-10", "type": "clause", "offset": [139, 149]}, {"key": "the-licensee-shall", "type": "clause", "offset": [163, 181]}, {"key": "to-the-university", "type": "clause", "offset": [190, 207]}, {"key": "reports-of", "type": "clause", "offset": [216, 226]}, {"key": "to-commercialize", "type": "definition", "offset": [282, 298]}, {"key": "licensed-technology", "type": "definition", "offset": [303, 322]}, {"key": "to-manufacture", "type": "definition", "offset": [327, 341]}, {"key": "offer-to-sell", "type": "clause", "offset": [343, 356]}, {"key": "licensed-products", "type": "definition", "offset": [366, 383]}], "hash": "20a057bc86152470d2f8de5e8db17f9e", "id": 3}, {"size": 9, "samples": [{"hash": "21jqhJHwbSo", "uri": "/contracts/21jqhJHwbSo#commercialization-reports", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.9952087402, "published": true}, {"hash": "bWfZFtNszMb", "uri": "/contracts/bWfZFtNszMb#commercialization-reports", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.77891922, "published": true}], "snippet": "Celgene will, with Jounce\u2019s cooperation CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH \u201c[***]\u201d. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. with respect to its activities under the U.S. Commercialization Plan, provide the JCC with a report, as soon as practicable but in no event later than [***] days following the end of each Calendar Quarter commencing as of and continuing after the Calendar Quarter in which the first Co-Co Product has received Regulatory Approval in the United States setting forth a summary written progress report on the status of its Commercialization Activities with respect to Co-Co Products and Co-Co Diagnostic Products, including the number of details made by any sales representatives of Co-Co Product in the United States during such Calendar Quarter (a \u201cU.S. Commercialization Report\u201d), as well as Celgene\u2019s plans with respect to Commercialization of Co-Co Products and Co-Co Diagnostic Products during the following [***] period. At least [***] prior to the anticipated First Co-Co Sale of a Co-Co Product under this Celgene Lead Co-Co Agreement in the United States, the JCC shall discuss and agree upon the form and content for such U.S. Commercialization Report. Such U.S. Commercialization Report shall also describe in reasonable detail the number of sales representatives dedicated to Commercialization of such products, the detailing strategy for such products, advertising, marketing and other promotional activities being conducted for such products, educational and scientific presentations to be made with respect to such products, actual and projected sales of such products, the key opinion leaders to be engaged with respect to such products, and other matters agreed upon by the JCC.", "snippet_links": [{"key": "this-exhibit", "type": "definition", "offset": [73, 85]}, {"key": "replaced-with", "type": "clause", "offset": [103, 116]}, {"key": "the-secretary", "type": "clause", "offset": [192, 205]}, {"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [209, 247]}, {"key": "confidential-treatment", "type": "definition", "offset": [286, 308]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [309, 325]}, {"key": "securities-act-of-1933", "type": "definition", "offset": [352, 374]}, {"key": "as-amended", "type": "definition", "offset": [376, 386]}, {"key": "with-respect-to", "type": "clause", "offset": [388, 403]}, {"key": "activities-under", "type": "clause", "offset": [408, 424]}, {"key": "the-us", "type": "clause", "offset": [425, 432]}, {"key": "commercialization-plan", "type": "definition", "offset": [434, 456]}, {"key": "provide-the", "type": "clause", "offset": [458, 469]}, {"key": "as-soon-as-practicable", "type": "definition", "offset": [489, 511]}, {"key": "in-no-event", "type": "clause", "offset": [516, 527]}, {"key": "following-the", "type": "definition", "offset": [550, 563]}, {"key": "calendar-quarter", "type": "definition", "offset": [576, 592]}, {"key": "regulatory-approval", "type": "clause", "offset": [698, 717]}, {"key": "in-the-united-states", "type": "clause", "offset": [718, 738]}, {"key": "progress-report", "type": "definition", "offset": [771, 786]}, {"key": "status-of", "type": "clause", "offset": [794, 803]}, {"key": "commercialization-activities", "type": "clause", "offset": [808, 836]}, {"key": "diagnostic-products", "type": "clause", "offset": [878, 897]}, {"key": "number-of", "type": "definition", "offset": [913, 922]}, {"key": "representatives-of", "type": "clause", "offset": [949, 967]}, {"key": "commercialization-report", "type": "definition", "offset": [1041, 1065]}, {"key": "prior-to-the", "type": "clause", "offset": [1228, 1240]}, {"key": "sale-of", "type": "clause", "offset": [1265, 1272]}, {"key": "form-and-content", "type": "clause", "offset": [1392, 1408]}, {"key": "other-promotional-activities", "type": "clause", "offset": [1679, 1707]}, {"key": "being-conducted", "type": "definition", "offset": [1708, 1723]}, {"key": "projected-sales", "type": "definition", "offset": [1837, 1852]}, {"key": "key-opinion-leaders", "type": "clause", "offset": [1875, 1894]}, {"key": "other-matters-agreed", "type": "clause", "offset": [1944, 1964]}], "hash": "b8428951c58ac5aec7810276f539bed3", "id": 4}, {"size": 8, "samples": [{"hash": "lTSAVLUMa5v", "uri": "/contracts/lTSAVLUMa5v#commercialization-reports", "label": "License and Collaboration Agreement (Zai Lab LTD)", "score": 28.6194381714, "published": true}, {"hash": "9Ej9W0VHffB", "uri": "/contracts/9Ej9W0VHffB#commercialization-reports", "label": "License and Collaboration Agreement (Zai Lab LTD)", "score": 28.5838470459, "published": true}, {"hash": "7ETThgDbP2F", "uri": "/contracts/7ETThgDbP2F#commercialization-reports", "label": "License and Collaboration Agreement (Paratek Pharmaceuticals, Inc.)", "score": 28.5838470459, "published": true}], "snippet": "Zai will update the JSC at each regularly scheduled JSC meeting regarding Zai\u2019s Commercialization activities with respect to the Licensed Products in the Territory. Each such update will be in a form to be agreed by the JSC and will summarize Zai\u2019s, its Affiliates\u2019 and Sublicensees\u2019 significant Commercialization activities with respect to the Licensed Products in the Territory, covering subject matter at a level of detail reasonably required by Paratek and sufficient to enable Paratek to determine Zai\u2019s compliance with its diligence obligations pursuant to Section 8.1. In addition, Zai will make available to Paratek such additional information about its Commercialization activities as may be reasonably requested by Paratek from time to time. For clarity, Zai will not be required to include information in its updates and reports under this Section 8.3 that it does not otherwise create for its own internal purposes. All updates and reports generated pursuant to this Section 8.3 shall be the Confidential Information of Zai.", "snippet_links": [{"key": "regularly-scheduled", "type": "definition", "offset": [32, 51]}, {"key": "commercialization-activities", "type": "clause", "offset": [80, 108]}, {"key": "with-respect-to", "type": "clause", "offset": [109, 124]}, {"key": "licensed-products", "type": "definition", "offset": [129, 146]}, {"key": "in-the-territory", "type": "clause", "offset": [147, 163]}, {"key": "agreed-by", "type": "definition", "offset": [206, 215]}, {"key": "subject-matter", "type": "clause", "offset": [390, 404]}, {"key": "level-of-detail", "type": "clause", "offset": [410, 425]}, {"key": "required-by", "type": "definition", "offset": [437, 448]}, {"key": "to-determine", "type": "definition", "offset": [490, 502]}, {"key": "compliance-with", "type": "definition", "offset": [509, 524]}, {"key": "diligence-obligations", "type": "definition", "offset": [529, 550]}, {"key": "section-81", "type": "clause", "offset": [563, 574]}, {"key": "in-addition", "type": "clause", "offset": [576, 587]}, {"key": "available-to", "type": "definition", "offset": [603, 615]}, {"key": "additional-information", "type": "clause", "offset": [629, 651]}, {"key": "requested-by", "type": "definition", "offset": [712, 724]}, {"key": "from-time-to-time", "type": "clause", "offset": [733, 750]}, {"key": "for-clarity", "type": "clause", "offset": [752, 763]}, {"key": "updates-and-reports", "type": "clause", "offset": [820, 839]}, {"key": "section-83", "type": "clause", "offset": [851, 862]}, {"key": "internal-purposes", "type": "clause", "offset": [909, 926]}, {"key": "confidential-information-of", "type": "clause", "offset": [1004, 1031]}], "hash": "2f20cc4f4646057062539e943d6aa546", "id": 5}, {"size": 7, "samples": [{"hash": "3m2W0E1B8hH", "uri": "/contracts/3m2W0E1B8hH#commercialization-reports", "label": "License Agreement (Y-mAbs Therapeutics, Inc.)", "score": 29.6433944702, "published": true}, {"hash": "8cWsDvkL95C", "uri": "/contracts/8cWsDvkL95C#commercialization-reports", "label": "License Agreement (Y-mAbs Therapeutics, Inc.)", "score": 29.6379184723, "published": true}, {"hash": "eR4QNb92eXm", "uri": "/contracts/eR4QNb92eXm#commercialization-reports", "label": "License Agreement (Y-mAbs Therapeutics, Inc.)", "score": 29.2518825531, "published": true}], "snippet": "LICENSEE, within thirty (30) days of the end of each Contract Half-Year, shall deliver to MSK true and accurate reports, giving such particulars of the business conducted by LICENSEE and its Sublicensees during the preceding six-month period under this Agreement. The reports shall include at least the following information, to be itemized per Licensed Product and/ or Licensed Service:\n(a) volumes, and unique identifiers (e.g., SKU or otherwise), of Licensed Products sold or otherwise distributed;\n(b) total revenue received on account of (i) Licensed Products sold or otherwise distributed, and (ii) other revenue bearing activities subject to payment hereunder;\n(c) Deductible Expenses (as provided in the definition of \u201cNet Sales\u201d);\n(d) Net Sales;\n(e) the portion of Net Sales that was received from Sublicensees;\n(f) total royalties due:\n(g) country of sale;\n(h) foreign currency conversion rate; and\n(i) any other consideration received in the prior quarter.", "snippet_links": [{"key": "within-thirty", "type": "clause", "offset": [10, 23]}, {"key": "deliver-to", "type": "definition", "offset": [79, 89]}, {"key": "accurate-reports", "type": "clause", "offset": [103, 119]}, {"key": "business-conducted", "type": "clause", "offset": [152, 170]}, {"key": "by-licensee", "type": "clause", "offset": [171, 182]}, {"key": "this-agreement", "type": "clause", "offset": [248, 262]}, {"key": "the-reports", "type": "clause", "offset": [264, 275]}, {"key": "licensed-service", "type": "definition", "offset": [370, 386]}, {"key": "unique-identifiers", "type": "definition", "offset": [405, 423]}, {"key": "products-sold", "type": "clause", "offset": [462, 475]}, {"key": "otherwise-distributed", "type": "definition", "offset": [479, 500]}, {"key": "total-revenue", "type": "definition", "offset": [506, 519]}, {"key": "received-on", "type": "clause", "offset": [520, 531]}, {"key": "other-revenue", "type": "definition", "offset": [605, 618]}, {"key": "subject-to", "type": "clause", "offset": [638, 648]}, {"key": "deductible-expenses", "type": "clause", "offset": [672, 691]}, {"key": "the-definition-of", "type": "definition", "offset": [708, 725]}, {"key": "net-sales", "type": "definition", "offset": [727, 736]}, {"key": "total-royalties-due", "type": "clause", "offset": [825, 844]}, {"key": "foreign-currency-conversion-rate", "type": "clause", "offset": [871, 903]}, {"key": "consideration-received", "type": "definition", "offset": [923, 945]}, {"key": "prior-quarter", "type": "definition", "offset": [953, 966]}], "hash": "b3de5b60eabf387f7c36cc7fe377d463", "id": 6}, {"size": 6, "samples": [{"hash": "ea5MYOCTSDq", "uri": "/contracts/ea5MYOCTSDq#commercialization-reports", "label": "License Agreement (Zai Lab LTD)", "score": 32.3538665771, "published": true}, {"hash": "dWfJQj0ksEe", "uri": "/contracts/dWfJQj0ksEe#commercialization-reports", "label": "License Agreement (Zai Lab LTD)", "score": 32.1622161865, "published": true}, {"hash": "cNH8sLpABgu", "uri": "/contracts/cNH8sLpABgu#commercialization-reports", "label": "License Agreement (Turning Point Therapeutics, Inc.)", "score": 31.6064338684, "published": true}], "snippet": "Zai shall update the JSC at each regularly scheduled JSC meeting regarding Zai\u2019s Commercialization activities with respect to the Products in the Territory. Each such update shall be in a form to be agreed by the JSC and shall summarize Zai\u2019s, its Affiliates\u2019 and Sublicensees\u2019 significant Commercialization activities with respect to the Products in the Territory, covering subject matter at a level of detail reasonably required by TPTX and sufficient to enable TPTX to determine Zai\u2019s compliance with its diligence obligations pursuant to Section 8.1. In addition, Zai shall make available to TPTX such additional information about its Commercialization activities as may be reasonably requested by TPTX from time to time. All updates and reports generated pursuant to this Section 8.3 shall be the Confidential Information of Zai.", "snippet_links": [{"key": "regularly-scheduled", "type": "definition", "offset": [33, 52]}, {"key": "commercialization-activities", "type": "clause", "offset": [81, 109]}, {"key": "with-respect-to", "type": "clause", "offset": [110, 125]}, {"key": "the-products", "type": "clause", "offset": [126, 138]}, {"key": "in-the-territory", "type": "clause", "offset": [139, 155]}, {"key": "agreed-by", "type": "definition", "offset": [199, 208]}, {"key": "subject-matter", "type": "clause", "offset": [375, 389]}, {"key": "level-of-detail", "type": "clause", "offset": [395, 410]}, {"key": "by-tptx", "type": "clause", "offset": [431, 438]}, {"key": "to-determine", "type": "definition", "offset": [469, 481]}, {"key": "compliance-with", "type": "definition", "offset": [488, 503]}, {"key": "diligence-obligations", "type": "definition", "offset": [508, 529]}, {"key": "section-81", "type": "clause", "offset": [542, 553]}, {"key": "in-addition", "type": "clause", "offset": [555, 566]}, {"key": "available-to", "type": "definition", "offset": [583, 595]}, {"key": "additional-information", "type": "clause", "offset": [606, 628]}, {"key": "requested-by", "type": "definition", "offset": [689, 701]}, {"key": "from-time-to-time", "type": "clause", "offset": [707, 724]}, {"key": "updates-and-reports", "type": "clause", "offset": [730, 749]}, {"key": "section-83", "type": "clause", "offset": [777, 788]}, {"key": "confidential-information-of", "type": "clause", "offset": [802, 829]}], "hash": "80183b5410cb91cd7dbc12ffab6969a7", "id": 7}, {"size": 6, "samples": [{"hash": "gi8NqCGkHFo", "uri": "/contracts/gi8NqCGkHFo#commercialization-reports", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.4544830322, "published": true}, {"hash": "9Uop5UAinMB", "uri": "/contracts/9Uop5UAinMB#commercialization-reports", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.421628952, "published": true}, {"hash": "6Dh96ZdWGv", "uri": "/contracts/6Dh96ZdWGv#commercialization-reports", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.3832988739, "published": true}], "snippet": "At the first meeting of the JRC following provision by Celgene to GlobeImmune of the draft Commercialization Plan pursuant to Section 4.3.2, and at each annual meeting thereafter with respect to a Licensed Product, Celgene will provide the JRC with a summary of its plans for Commercialization of each Licensed Product, and will provide the JRC with any updates and revisions to the Commercialization Plan for each Licensed Product in accordance with Section 4.3.2. [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.", "snippet_links": [{"key": "the-first-meeting", "type": "definition", "offset": [3, 20]}, {"key": "the-jrc", "type": "clause", "offset": [24, 31]}, {"key": "by-celgene", "type": "clause", "offset": [52, 62]}, {"key": "commercialization-plan", "type": "definition", "offset": [91, 113]}, {"key": "pursuant-to-section", "type": "definition", "offset": [114, 133]}, {"key": "annual-meeting", "type": "clause", "offset": [153, 167]}, {"key": "with-respect-to", "type": "clause", "offset": [179, 194]}, {"key": "licensed-product", "type": "definition", "offset": [197, 213]}, {"key": "provide-the", "type": "clause", "offset": [228, 239]}, {"key": "plans-for", "type": "clause", "offset": [266, 275]}, {"key": "updates-and-revisions", "type": "clause", "offset": [354, 375]}, {"key": "in-accordance-with", "type": "clause", "offset": [432, 450]}, {"key": "certain-confidential-information", "type": "clause", "offset": [472, 504]}, {"key": "contained-in", "type": "definition", "offset": [505, 517]}, {"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [567, 605]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [606, 622]}, {"key": "securities-act-of-1933", "type": "definition", "offset": [634, 656]}, {"key": "as-amended", "type": "definition", "offset": [658, 668]}], "hash": "5eb4f86d4386b2d1a02b322046d28d9b", "id": 8}, {"size": 5, "samples": [{"hash": "ahixGb5o3mb", "uri": "/contracts/ahixGb5o3mb#commercialization-reports", "label": "Amendment and Restatement Agreement (Mereo BioPharma Group PLC)", "score": 36.2306632996, "published": true}, {"hash": "e7rGI7d7pxV", "uri": "/contracts/e7rGI7d7pxV#commercialization-reports", "label": "Exclusive License and Option Agreement", "score": 31.3408622742, "published": true}, {"hash": "ilVo8UqONaQ", "uri": "/contracts/ilVo8UqONaQ#commercialization-reports", "label": "Exclusive License and Option Agreement (Mereo Biopharma Group PLC)", "score": 30.0650234222, "published": true}], "snippet": "Without limiting Section 5.4, within [***] days following the end of each [***], during the Royalty Term, Mereo shall provide to AstraZeneca a written summary of the Commercialization activities it has performed, or caused to be performed, including a summary of all relevant financial data relating to such activities since the preceding report.", "snippet_links": [{"key": "section-54", "type": "clause", "offset": [17, 28]}, {"key": "following-the", "type": "definition", "offset": [48, 61]}, {"key": "royalty-term", "type": "clause", "offset": [92, 104]}, {"key": "provide-to", "type": "clause", "offset": [118, 128]}, {"key": "summary-of-the", "type": "clause", "offset": [151, 165]}, {"key": "commercialization-activities", "type": "clause", "offset": [166, 194]}, {"key": "financial-data", "type": "clause", "offset": [276, 290]}, {"key": "relating-to", "type": "definition", "offset": [291, 302]}], "hash": "05640e462159fe9e5fe2c6a0bacd6c18", "id": 9}, {"size": 5, "samples": [{"hash": "2sDyzVnaJQG", "uri": "/contracts/2sDyzVnaJQG#commercialization-reports", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 37.2902121834, "published": true}, {"hash": "ePTlG1r6D3N", "uri": "/contracts/ePTlG1r6D3N#commercialization-reports", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 37.0985626283, "published": true}, {"hash": "42jemUzzxtM", "uri": "/contracts/42jemUzzxtM#commercialization-reports", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 36.0444908142, "published": true}], "snippet": "On a Calendar Quarter basis, each Party will provide a report setting forth the results of activities conducted by or on behalf of such Party during such Calendar Quarter, and the JSC will review and discuss such reports.", "snippet_links": [{"key": "calendar-quarter", "type": "definition", "offset": [5, 21]}, {"key": "provide-a", "type": "definition", "offset": [45, 54]}, {"key": "of-activities", "type": "clause", "offset": [88, 101]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [112, 130]}, {"key": "such-party", "type": "clause", "offset": [131, 141]}], "hash": "6c3c90db82ef5981909dfe54701c8e1d", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IiJjb21tZXJjaWFsaXphdGlvbi1yZXBvcnRzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"children": [["upfront-payment", "Upfront Payment"], ["royalty-term", "Royalty Term"], ["taxes", "Taxes"], ["upfront-cash-payment", "Upfront Cash Payment"], ["royalty", "Royalty"]], "size": 483, "parents": [["commercialization", "Commercialization"], ["development-and-commercialization", "Development and Commercialization"], ["definitions", "DEFINITIONS"], ["reports", "Reports"], ["reports-records-and-payments", "Reports Records and Payments"]], "title": "Commercialization Reports", "id": "commercialization-reports", "related": [["development-reports", "Development Reports", "Development Reports"], ["commercialization-plan", "Commercialization Plan", "Commercialization Plan"], ["research-reports", "Research Reports", "Research Reports"], ["development-plan", "Development Plan", "Development Plan"], ["development-activities", "Development Activities", "Development Activities"]], "related_snippets": [], "updated": "2026-04-19T05:56:19+00:00", "also_ask": ["What key data and metrics must be included in effective commercialization reports?", "How can reporting obligations be structured to ensure compliance without overburdening the reporting party?", "What are the most common pitfalls or ambiguities in commercialization reporting clauses?", "How do courts typically assess the sufficiency and timeliness of commercialization reports in disputes?", "How do reporting requirements in this agreement compare to industry standards or similar contracts?"], "drafting_tip": "Specify reporting frequency and required content to ensure consistent and comprehensive updates; define submission deadlines to promote timely compliance.", "explanation": "The Commercialization Reports clause requires a party, typically a licensee, to provide regular updates on the progress and activities related to the commercialization of a licensed product or technology. These reports often include information such as sales figures, marketing efforts, development milestones, and future plans. By mandating these disclosures, the clause ensures that the licensor can monitor the licensee\u2019s efforts and compliance with commercialization obligations, thereby promoting transparency and accountability in the business relationship."}, "json": true, "cursor": ""}}